Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum-resistant recurrent ovarian cancer. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the signaling pathway.
Market Cap | 25.827 Million | Shares Outstanding | 28.825 Million | Avg 30-day Volume | 89.382 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.66 |
Price to Revenue | 19.5042 | Debt to Equity | 0.1338 | EBITDA | -28.969 Million |
Price to Book Value | 2.3074 | Operating Margin | -541.4952000000001 | Enterprise Value | 56.772 Million |
Current Ratio | 6.52 | EPS Growth | -0.229 | Quick Ratio | 6.399 |
1 Yr BETA | 1.0342 | 52-week High/Low | 4.4 / 0.8 | Profit Margin | -537.2559 |
Operating Cash Flow Growth | 28.7571 | Altman Z-Score | -7.4583 | Free Cash Flow to Firm | -3.739 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
GELLER ROBERT B. CHIEF MEDICAL OFFICER |
|
0 | 2022-07-01 | 2 |
HOWARD RUDY CHIEF FINANCIAL OFFICER |
|
0 | 2022-06-03 | 2 |
ESHELMAN FREDRIC N EXECUTIVE CHAIRMAN OF BOARD |
|
9,211,769 | 2022-04-01 | 4 |
DOVE LEONARD SCOTT CHIEF OPERATING OFFICER |
|
200,000 | 2022-03-21 | 2 |
MCINTYRE GAIL FRANCES CEO AND PRESIDENT |
|
425,000 | 2022-01-24 | 1 |
SHAH VINAY CHIEF FINANCIAL OFFICER |
|
175,000 | 2022-01-24 | 1 |
RANGWALA RESHMA CHIEF MEDICAL OFFICER |
|
175,000 | 2022-01-24 | 1 |
|
941,880 | 2021-12-03 | 3 | |
|
22,812 | 2021-09-10 | 1 | |
|
22,812 | 2021-09-10 | 1 | |
|
22,812 | 2021-09-10 | 1 | |
|
22,812 | 2021-09-10 | 1 | |
|
22,812 | 2021-09-10 | 1 | |
|
0 | 2020-09-14 | 0 | |
|
No longer subject to file | 2020-04-08 | 0 | |
|
No longer subject to file | 2020-04-08 | 0 | |
|
No longer subject to file | 2020-04-08 | 0 | |
|
No longer subject to file | 2020-04-08 | 0 | |
|
0 | 2019-09-12 | 0 | |
HAAS KEVIN VP, FINANCE AND PAO |
|
0 | 2019-02-28 | 0 |
|
0 | 2019-01-03 | 3 | |
SHEPARD JAY PRESIDENT AND CEO SHEPARD JAY PRESIDENT AND CEO |
|
84,113 | 2018-12-21 | 0 |
WESTBERG PAUL SVP AND CHIEF BUSINESS OFFICER |
|
225,124 | 2018-06-15 | 0 |
STOUT JAY S SVP, TECHNICAL OPERATIONS |
|
185,646 | 2018-04-24 | 0 |
WOODY TRACY M CHIEF COMMERCIAL OFFICER |
|
215,755 | 2018-03-23 | 0 |
WARD SHANE SVP AND GENERAL COUNSEL |
|
201,556 | 2018-02-08 | 0 |
|
18,160 | 2017-12-20 | 0 | |
|
44,380 | 2017-12-20 | 0 | |
|
22,380 | 2017-12-20 | 0 | |
|
23,880 | 2017-12-20 | 0 | |
|
22,280 | 2017-12-20 | 0 | |
GUT ROBERT CHIEF MEDICAL OFFICER |
|
227,300 | 2017-12-20 | 0 |
HISLOP COLIN CHIEF MEDICAL OFFICER |
|
23,833 | 2017-10-19 | 0 |
BRUMM JOSHUA T COO AND CFO |
|
201,269 | 2017-10-19 | 0 |
|
No longer subject to file | 2017-09-21 | 0 | |
CLELAND JEFFREY L PRESIDENT AND CEO |
|
121,548 | 2015-04-14 | 0 |
NEW LEAF VENTURE ASSOCIATES II, L.P. |
|
No longer subject to file | 2014-12-18 | 0 |
|
19,161 | 2014-11-24 | 0 | |
NEW LEAF VENTURE ASSOCIATES II, L.P. |
|
3,359,374 | 2014-09-29 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-07-05 12:06:46 -0400 | 2022-07-01 | A | 200,000 | a | 200,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ARAVIVE INC ARAV | 2022-08-12 22:15:03 UTC | 1.2968 | 1.0232 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 21:45:04 UTC | 1.2968 | 1.0232 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 21:15:04 UTC | 1.2968 | 1.0232 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 20:45:04 UTC | 1.2969 | 1.0231 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 20:15:05 UTC | 1.2969 | 1.0231 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 19:45:03 UTC | 1.2969 | 1.0231 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 19:15:05 UTC | 1.2969 | 1.0231 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 18:45:03 UTC | 1.2969 | 1.0231 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 18:15:04 UTC | 1.2969 | 1.0231 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 17:45:04 UTC | 1.2969 | 1.0231 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 17:15:05 UTC | 1.2969 | 1.0231 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 16:45:04 UTC | 1.2969 | 1.0231 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 16:15:04 UTC | 1.2969 | 1.0231 | 350000 |
ARAVIVE INC ARAV | 2022-08-12 15:45:04 UTC | 1.2969 | 1.0231 | 300000 |
ARAVIVE INC ARAV | 2022-08-12 15:15:05 UTC | 1.2969 | 1.0231 | 300000 |
ARAVIVE INC ARAV | 2022-08-12 14:45:04 UTC | 1.2969 | 1.0231 | 300000 |
ARAVIVE INC ARAV | 2022-08-12 14:15:05 UTC | 1.2969 | 1.0231 | 300000 |
ARAVIVE INC ARAV | 2022-08-12 13:45:04 UTC | 1.2969 | 1.0231 | 300000 |
ARAVIVE INC ARAV | 2022-08-12 13:15:04 UTC | 1.2969 | 1.0231 | 300000 |
ARAVIVE INC ARAV | 2022-08-12 12:45:04 UTC | 1.2969 | 1.0231 | 300000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|